{"indexed":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T10:02:26Z","timestamp":1515751346627},"reference-count":11,"publisher":"Cambridge University Press (CUP)","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec id=\"S0899823X15000069_abs1\" sec-type=\"general\">\n               <jats:title>OBJECTIVE<\/jats:title>\n               <jats:p>To determine whether a difference in antibody to hepatitis B surface antigen (anti-HBs) response to a hepatitis B vaccine challenge dose existed among persons with a baseline anti-HBs level of 0 mIU\/mL (group 1) and those with \u201cnon-zero\u201d levels of 0.1\u20134.9 (group 2) and 5.0\u20139.9 (group 3) mIU\/mL, according to the VITROS ECi anti-HBs assay.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs2\" sec-type=\"general\">\n               <jats:title>DESIGN<\/jats:title>\n               <jats:p>Subanalysis of randomized clinical trial. Response was defined as a postchallenge anti-HBs level of at least 10 mIU\/mL and 4-fold rise in anti-HBs level 2 weeks after a single challenge dose of 10 vs 20 \u00b5g Engerix-B. Baseline was defined as the anti-HBs level immediately before administration of the challenge dose.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs3\" sec-type=\"general\">\n               <jats:title>SETTING<\/jats:title>\n               <jats:p>Pediatric integrated healthcare system near Houston, Texas.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs4\" sec-type=\"general\">\n               <jats:title>PARTICIPANTS<\/jats:title>\n               <jats:p>Three hundred nineteen US-born 16\u201319-year-olds who completed the hepatitis B vaccine series during the first year of life.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs5\" sec-type=\"results\">\n               <jats:title>RESULTS<\/jats:title>\n               <jats:p>One hundred seventy-eight persons had zero (group 1) and 141 (114 group 2 and 27 group 3) had non-zero anti-HBs levels at baseline. Response to the challenge dose was significantly higher among those with non-zero vs zero anti-HBs levels, irrespective of challenge dosage; only 1 person with a non-zero anti-HBs level failed to respond to the challenge dose (group 3, 27\/27 [100%] vs group 2, 113\/114 [99%] vs group 1, 145\/178 [82%]; <jats:italic>P<\/jats:italic>&amp;lt;.0001).<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs6\" sec-type=\"conclusions\">\n               <jats:title>CONCLUSIONS<\/jats:title>\n               <jats:p>Among participants with residual anti-HBs levels less than 10 mIU\/mL 16\u201319 years after primary hepatitis B vaccination during infancy, non-zero anti-HBs levels, with rare exception, indicated persistence of immune memory to HBsAg.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec id=\"S0899823X15000069_abs7\" sec-type=\"general\">\n               <jats:title>TRIAL REGISTRATION<\/jats:title>\n               <jats:p>ClinicalTrials.gov Identifier: NCT01341275<\/jats:p>\n               <jats:p>\n                  <jats:italic>Infect Control Hosp Epidemiol<\/jats:italic> 2015;00(0):1\u20135<\/jats:p>\n            <\/jats:sec>","DOI":"10.1017\/ice.2015.6","type":"article-journal","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T07:32:13Z","timestamp":1422948733000},"page":"529-533","source":"Crossref","is-referenced-by-count":6,"title":"Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen","prefix":"10.1017","volume":"36","author":[{"given":"Philip R.","family":"Spradling","affiliation":[]},{"given":"Saleem","family":"Kamili","affiliation":[]},{"given":"Jian","family":"Xing","affiliation":[]},{"given":"Jan","family":"Drobeniuc","affiliation":[]},{"given":"Dale J.","family":"Hu","affiliation":[]},{"given":"Amy B.","family":"Middleman","affiliation":[]}],"member":"56","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"S0899823X15000069_ref6","DOI":"10.1016\/S0264-410X(96)00205-8","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref4","DOI":"10.1542\/peds.2013-2940","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref3","DOI":"10.7326\/0003-4819-154-6-201103150-00004","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref2","DOI":"10.1093\/cid\/cir270","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref1","volume":"54","first-page":"1","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"S0899823X15000069_ref7","DOI":"10.1016\/S0264-410X(01)00112-8","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref11","DOI":"10.1086\/314578","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref10","DOI":"10.1016\/0264-410X(96)00062-X","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref9","DOI":"10.1056\/NEJM198010093031501","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref8","DOI":"10.1128\/CVI.00694-12","doi-asserted-by":"publisher"},{"key":"S0899823X15000069_ref12","volume":"62","first-page":"1","year":"2013","journal-title":"MMWR Recomm Rep"}],"container-title":"Infection Control & Hospital Epidemiology","original-title":[],"link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X15000069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T12:39:00Z","timestamp":1492951140000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":11,"alternative-id":["S0899823X15000069"],"URL":"http:\/\/dx.doi.org\/10.1017\/ice.2015.6","relation":{"cites":[]},"ISSN":["0899-823X","1559-6834"],"subject":["Microbiology (medical)","Epidemiology","Infectious Diseases"],"container-title-short":"Infect. Control Hosp. Epidemiol."}